Novartis Investigative Site

Kędzierzyn-Koźle 47 220

0 studies enrolling now · 2 studies all time

What they study most

Cardiovascular Disease and Lipoprotein(a)

Studies at this site

• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed